← Companies|Meiji Pharma
Me

Meiji Pharma

Tokyo JPFounded 19467,000 employees
Private CappharmaPrivateInfectious DiseaseCNS
Platform: Meiact Antibiotic
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
FixacageneMEI-7762Preclinical1Small MoleculePI3KαCAR-T BCMANSCLC
PexatenlimabMEI-7772Approved2Gene EditingEZH2CAR-T BCMAEwing Sarcoma
TiravorutinibMEI-2255Preclinical1PeptideGLP-1RTNFiCRCGastric Ca
MEI-1324MEI-1324Preclinical2ASOKRASG12CSOS1iFSGSSMA
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)
2025-05-21
Tiravorutinib Interim
Gastric Ca
Past
2026-05-08
Pexatenlimab Ph3 Readout
Ewing Sarcoma
Ph3 Readout
2027-06-23
Fixacagene Interim
NSCLC
Interim
2028-10-26
Pexatenlimab Ph3 Readout
Ewing Sarcoma
Ph3 Readout
2029-03-09
MEI-1324 Interim
Cholangiocarcinoma
Interim